RVMD — Revolution Medicines, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1628171 ·
Last close
$162.69
Market Cap
$35.19B
52W High
$224.31
52W Low
$67.86
ADV30
2,415,533
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 197,559,000 197,232,000 -373,149,000 -407,457,000 4,303,514,000 615,908,000 1,902,011,000
Jun 2026 0 — -505,132,000 -644,371,000 4,323,270,000 815,435,000 1,717,032,000
Mar 2026 0 — -445,222,000 -453,816,000 2,253,737,000 440,939,000 753,820,000
Dec 2025 0 — -361,626,000 -364,892,000 2,354,508,000 383,745,000 723,211,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,431,372,000
Investing CF
$-1,331,075,000
Financing CF
$3,171,885,000
CapEx
$-9,445,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.11
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,374,746,000
Inventory
$11,018,000
Receivables
$230,724,000
ST Investments
$3,035,477,000
EBIT TTM
$-1,791,171,000
Pretax Income TTM
$-1,872,889,000
Interest Exp TTM
$81,718,000
Analysts
24

Yahoo Snapshot (yfinance, live)

Total Revenue
$197,559,008
EBITDA
$-1,675,138,944
Free Cash Flow
$-886,292,352
Enterprise Value
$39,148,716,032
Total Cash
$3,651,385,088
Total Debt
$1,211,414,016
Shares Out
216,292,323
Trailing EPS
$-9.13
Book Value
$11.11
ROE
-93.6%
ROA
-32.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -1,182,369,000 -1,131,301,000 2,354,508,000 723,211,000 1,631,297,000 -897,741,000
Dec 2024 0 -689,524,000 -600,093,000 2,558,301,000 293,097,000 2,265,204,000 -557,436,000
Dec 2023 11,580,000 -487,185,000 -436,367,000 2,061,705,000 235,511,000 1,826,194,000 -350,572,000
Dec 2022 35,380,000 -258,279,000 -248,705,000 811,930,000 126,742,000 685,188,000 -224,401,000

TTM Snapshot

Revenues TTM
$7,768,000
NetIncome TTM
$-1,768,285,000
OpCashFlow TTM
—
Assets (Latest)
$4,323,270,000
Forward EPS
$-4.33

Max Pain — expiry 2026-12-18

max pain strike: $180.00 · spot: $159.82 · call oi: 5,616 · put oi: 7,356
Expected Move to 2026-12-18: ±$21.80 (13.64%) — implied range $138.02 – $181.62 · ATM straddle on $160.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BIIB BIOGEN INC. $37.07B $250.79 —
BNTX BioNTech SE $21.32B $84.86 —
ARGX ARGENX SE $58.92B $947.52 —
NBIX NEUROCRINE BIOSCIENCES INC $16.79B $165.92 —
EXEL EXELIXIS, INC. $16.71B $68.50 —

News headlines (Yahoo Finance, 1h cache)

Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
2026-11-17 17:13 · Yahoo
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
2026-11-16 18:00 · Yahoo
RevMed CEO on tackling “complex” launch for wonder pancreatic drug
2026-11-16 17:15 · Yahoo
What Sent Revolution Medicines Stock Lower?
2026-11-12 15:45 · Yahoo
Stanley Druckenmiller’s Best Buy Is Already Up 29%. Is It Too Late to Follow Him?
2026-11-11 05:03 · Yahoo
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
2026-11-10 13:55 · Yahoo
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
2026-11-08 16:35 · Yahoo
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
2026-11-08 15:35 · Yahoo
Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats Up
2026-11-07 19:12 · Yahoo
Revolution Medicines Stock Gets A Lift From Pancreatic Cancer Drug Launch
2026-11-07 09:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.